NovaVision Inc. Acquired by Neurological Medical Device Innovator Vycor Medical Inc.

There’s renewed hope for tens of millions worldwide with neurological vision loss who erroneously believe blindness due to stroke, brain cancer or brain injury to be untreatable. Medical device innovator Vycor Medical, Inc. (OTCBB: VYCO) has acquired NovaVision, Inc. (www. NovaVision.com), the only provider of progressive, scientifically based technologies that reverse and restore neurological visual loss. Together the companies will promote NovaVision’s FDA-approved, non-invasive light stimulation-based Vision Restoration Therapy (VRT) platform clinically proven to permanently restore lost vision resulting from stroke, brain cancer, traumatic or other acquired brain injury. “On average VRT patients permanently recover 5 degrees of central vision, a critical gain for conducting many daily activities,” Tom Bridges NovaVision vice president of sales and marketing notes. More than 10 years of research and data support the efficacy of NovaVision’s neurostimulation therapy approach. The medical devise is expected to be available by a prescription from any ophthamologist, neurologist or physiatrist in the U.S.